A Smart + Strong Site
Subscribe to:
POZ magazine
AIDS viruselvitegravir belongs to a class of anti-HIV drugs called Integrase Inhibitors. For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.

Elvitegravir is being developed by Gilead Sciences. They have a useful web site that includes the latest news & research reports on this and other drugs in development: click here.

AIDS drugs chartOur quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
news Treatment News
Search for recent news and archived stories about elvitegravir.
forumsHave more questions? Then post a question or comment in our Community Forums.
Help Paying for MedsHelp Paying for Meds: Patient assistance and co-pay programs for HIV and viral hepatitis drugs.
Lessons Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
Collapse All

Recommended Reading List:

Books about AIDS & HIV treatmentsFor a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from Amazon.com, click here.

Elvitegravir (GS-9137)

Pronunciation(s): el-vye-TEG-ra-veer

What is elvitegravir?
  • Elvitegravir is an integrase inhibitor by Gilead Sciences. It is a component of the approved fixed-dose combination tablet Stribild and is currently being reviewed by the U.S. Food and Drug Administration for possible approval as a stand-alone antiretroviral for use in combination with other HIV drugs.
  • After HIV's genetic material is deposited inside a cell, its RNA must be converted (reverse transcribed) into DNA. A viral enzyme called integrase then helps to hide HIV's DNA inside the cell's DNA. Once this happens, the cell can begin producing genetic material for new viruses. Integrase inhibitors, such as elvitegravir, are designed to block the activity of the integrase enzyme and to prevent HIV DNA from entering healthy cell DNA.
  • Elvitegravir will need to be used in combination with other drugs. Clinical trials continue to evaluate its effect in combination with other drugs, including those currently approved for the treatment of HIV.

What is already known about elvitegravir?
  • The elvitegravir doses being explored in clinical trials are 85 mg or 150 mg once daily, combined with 100mg Norvir (ritonavir) or Gilead's experimental pharmacokinetics enhancer cobicistat. Norvir or cobicistat is used to boost elvitegravir in the bloodstream, making it more effective against HIV.
  • Elvitegravir, especially when combined with Norvir or cobicistat, might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
  • Elvitegravir holds promise for HIV-positive patients who have taken other HIV drugs in the past. Because elvitegravir targets HIV differently than most available drugs, chances are that many people living with the virus—notably those who haven't used another integrase inhibitor (e.g., Isentress)—will likely benefit from using elvitegravir.
  • A major Phase III clinical trial is comparing Norvir-boosted elvitegravir to Isentress in people living with HIV who have used other antiretrovirals in the past. Forty eight-week data from the clinical trial (Study 145) were reported at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome. In summary, the results demonstrated that elvitegravir works just as well as Isentress in treatment-experienced patients, when both drugs are combined with a boosted protease inhibitor and a third antiretroviral.

What about drug interactions?
  • Studies on potential interactions between elvitegravir and other drugs have not yet been reported, but are planned and ongoing.

What is known about side effects?
  • According to clinical trial results reported to date, the most common side effects associated with therapy that includes elvitegravir include nausea and diarrhea, upper respiratory tract infections and broncitis, back and joint pain and urinary tract infections. While elvitegravir appears more likely to be associated with diarrhea than Isentress, it appears less likely to cause liver enzyme increases than Isentress.

Who should not take elvitegravir?
  • It is not known whether elvitegravir will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
  • It is not known whether elvitegravir passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.

Where can I learn more about clinical trials of elvitegravir?
  • If you would like to find out if you are eligible for any clinical trials that include elvitegravir, visit ClinicalTrials.gov, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email contactus@aidsinfo.nih.gov.

Last Revised: August 28, 2012

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.